Metal nanoparticles (NPs), particularly gold nanorods (AuNRs), appear as excellent platforms not only to transport and deliver bioactive cargoes but also to provide additional therapeutic responses for diseased cells and tissues and/or to complement the action of the carried molecules. In this manner, here, we optimized a previous developed metal-based nanoplatform composed of an AuNR core surrounded by a polymeric shell constructed by means of the layer-by-layer approach, and in which very large amounts of the antineoplasic drug doxorubicin (DOXO) in a single loading step and targeting capability thanks to an outer hyaluronic acid layer were incorporated by means of an optimized fabrication process (PSS/DOXO/PLL/HA-coated AuNRs). The platform retained its nanometer size with a negative surface charge and was colloidally stable in a range of physiological conditions, in which only in some of them some particle clustering was noted with no precipitation. In addition, the dual stimuli-responsiveness of the designed nanoplatform to both endogenous proteases and external applied light stimuli allows to perfectly manipulate the chemodrug release rates and profiles to achieve suitable pharmacodynamics. It was observed that the inherent active targeting abilities of the nanoplatfom allow the achievement of specific cell toxicity in tumoral cervical HeLa cells, whilst healthy ones such as 3T3-Balb fibroblast remain safe and alive in agreement with the detected levels of internalization in each cell line. In addition, the bimodal action of simultaneous chemo- and photothermal bioactivity provided by the platform largely enhances the therapeutic outcomes. Finally, it was observed that our PSS/DOXO/PLL/HA-coated AuNRs induced cell mortality mainly through apoptosis in HeLa cells even in the presence of NIR light irradiation, which agrees with the idea of the chemo-activity of DOXO predominating over the photothermal effect to induce cell death, favoring an apoptotic pathway over necrosis for cell death.
Cardiovascular disease (CVD) is a general term that includes diseases that affect the circulatory system and/or the heart. Their underlying pathology is atherosclerosis, an inflammatory disease characterized by the accumulation of lipids, inflammatory cells and fibrous tissue in the arteries' internal wall, provoking to some extent their obstruction. Atherosclerosis is still addressed as a simple disease instead of the complex interplay of different types of cells and cascade signaling pathways, so the use of any single imaging or therapeutic agent alone is unlikely to provide a satisfactory outcome. Hence, other treatment strategies need to be implemented, in particular, those using new nanomaterials able to target the plaque and to efficiently treat it, and that can be easily released by the body without provoking adverse effects. With this background, we have designed a biocompatible drug delivery vehicle that efficiently loads and protects the drug Atorvastatin (ATO reduces the LDL levels) while a folate receptor in the external shell targets inflamed areas. To avoid the common toxic effects of folic acid (FA) or ATO in the body at certain concentrations, the vehicle will provide covalent attachment for the FA on the surface and cage structure for ATO protection. To complement the treatment, genetic material will be included in a separate compartment to actively influence the regulation of immune responses and inflammatory disorders.